0001192482-18-000037.txt : 20180112
0001192482-18-000037.hdr.sgml : 20180112
20180112161550
ACCESSION NUMBER: 0001192482-18-000037
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180110
FILED AS OF DATE: 20180112
DATE AS OF CHANGE: 20180112
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fleming Alison B
CENTRAL INDEX KEY: 0001640701
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37372
FILM NUMBER: 18526151
MAIL ADDRESS:
STREET 1: 780 DEDHAM STREET, SUITE 800
CITY: CANTON
STATE: MA
ZIP: 02021
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: COLLEGIUM PHARMACEUTICAL, INC
CENTRAL INDEX KEY: 0001267565
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: VA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 780 DEDHAM STREET, SUITE 800
CITY: CANTON
STATE: MA
ZIP: 02021
BUSINESS PHONE: 781-713-3699
MAIL ADDRESS:
STREET 1: 780 DEDHAM STREET, SUITE 800
CITY: CANTON
STATE: MA
ZIP: 02021
FORMER COMPANY:
FORMER CONFORMED NAME: COLLEGIUM PHARMACEUTICAL INC
DATE OF NAME CHANGE: 20031020
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2018-01-10
0001267565
COLLEGIUM PHARMACEUTICAL, INC
COLL
0001640701
Fleming Alison B
C/O COLLEGIUM PHARMACEUTICAL, INC.
780 DEDHAM STREET, SUITE 800
CANTON
MA
02021
0
1
0
0
Chief Technology Officer
Common Stock
2018-01-10
4
M
0
6928
.48
A
32651
D
Common Stock
2018-01-10
4
S
0
6928
19.07
D
25723
D
Stock option (right to purchase)
.48
2018-01-10
4
M
0
6928
0
D
2023-01-24
Common Stock
6928
5753
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2017.
The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
All of the options were fully vested and exercisable as of January 10, 2018.
/s/ Paul Brannelly as Attorney-In-Fact For Alison B. Fleming
2018-01-12